Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resentive resistant human breast cancer cells to 40-H tamoxifen

European Journal of Endocrinology

Volumn 153, Issue 4, 2005, Pages 613-625

  Günbert, Andreas R ^a   Grünker, Carsten ^a   Olota, Agnes ^a   Läsche, Julia ^a   Eicke, Nicola ^a   Emons, Günter ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GONADORELIN AGONIST; GONADORELIN DERIVATIVE; GONADORELIN[6 DEXTRO LYSINE]; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN P185; TRIPTORELIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SUBPOPULATION; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME ACTIVATION; GENE OVEREXPRESSION; HORMONE ACTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; ESTROGEN ANTAGONISTS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TAMOXIFEN; TRIPTORELIN;

EID: 27644458748     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01996     Document Type: Article

References (51)

1. 6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor, and sex steroids in 500 biopsy samples of human breast cancer. Journal of Clinical Laboratory Analysis 1989 3 137-147.
2. Baumann KH, Kiesel L, Kaufmann M, Bastert G & Runnebaum B. Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Research and Treatment 1993 25 37-46.
3. Moriya T, Suzuki T, Pilichowska M, Ariga N, Kimura N, Ouchi N, Nagura H & Sasano H. Immunohistochemical expression of gonadotropin releasing hormone receptor in human breast carcinoma. Pathology International 2001 51 333-337.
4. Mangia A, Tommasi S, Reshkin SJ, Simone G, Stea B, Schittulli F & Paradiso A. Gonadotropin releasing hormone receptor expression in primary breast cancer: comparison of immunohistochemical, radioligand and Western blot analyses. Oncology Reports 2002 6 1127-1132.
5. Miller WR, Scott WN, Morris R, Fraser HM & Sharpe RM. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 1985 313 231-233.
6. Blankenstein MA, Henkelmann MS & Klijn JG. Direct inhibitory effect of a luteinizing hormone-releasing hormone agonist on MCF-7 human breast cancer cells. European Journal of Cancer and Clinical Oncology 1985 21 1493-1499.
7. Foekens JA, Henkelmann MS, Fukkink JF, Blankenstein MA & Klijn JG. Combined effects of buserilin, estradiol and tamoxifen on the growth of MCF-7 human breast cancer cells in vitro. Biochemical and Biophysical Research Communications 1986 140 550-556.
8. Eidne KA, Flanagan CA, Harris NS & Millar RP. Gonadotropin releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH-agonists. Journal of Clinical Endocrinology and Metabolism 1987 64 425-432.
9. Neri C, Berthois Y, Schatz B, Drieu K & Martin PM. Compared effects of GnRH analogs and 4-hydroxytamoxifen on growth and steroid receptors in antiestrogen sensitive and resistant MCF-7 breast cancer sublines. Breast Cancer Research and Treatment 1990 15 85-93.
10. Scott WN, Mullen P & Miller WR. Factors influencing the response of MCF-7 cells to an agonist of luteinising hormone-releasing hormone. European Journal of Cancer 1991 27 1458-1461.
11. Hershkovitz E, Marbach M, Bosin E, Levy J, Roberts CT Jr, LeRoith D, Schally AV & Sharoni Y. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factors. Journal of Clinical Endocrinology and Metabolism 1993 77 963-968.
12. Szepeshazy K, Milovanovic S, Lapis K, Groot K & Schally AV. Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Research and Treatment 1992 21 181-192.
13. Chen A, Kaganovsky E, Rahimipour S, Ben-Aroya N, Okon E & Koch Y. Two forms of gonadotropin-releasing hormone (GnRH) are expressed in human breast tissue and overexpressed in breast cancer: a putative mechanism for the antiproliferative effect of GnRH by down-regulation of acidic ribosomal phosphoproteins P1 and P2. Cancer Research 2002 62 1036-1044.
14. Gründker C, Völker P, Schulz KD & Emons G. Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. Gynecologic Oncology 2000 78 194-202.
15. Emons G, Müller V, Ortmann O, Grossmann G, Trautner U, v Stuckrad B, Schulz KD & Schally AV. Luteinizing hormone-releasing hormone agonist triptorelin antagonizes signal transduction and mitogenic activity of epidermal growth factor in human ovarian and endometrial cancer cell lines. International Journal of Oncology 1996 9 1129-1137.
16. I-mediated activation of phosphotyrosine phosphatase. Endocrinology 2001 142 2369-2380.
17. Gründker C, Günthert AR, Westphalen S & Emons G. Biology of GnRH systems in human gynecological cancers. European Journal of Endocrinology 2002 146 1-14.
18. Gründker C, Günthert AR, Hellriegel M & Emons G. Gonadotropin-releasing hormone (GnRH) agonist triptorelin inhibits estradiol-induced serum response element (SRE) activation and c-fos expression in human endometrial, ovarian and breast cancer cells. European Journal of Endocrinology 2004 151 619-628.
19. Gründker C, Schulz K, Günthert AR & Emons G. Luteinizing hormone-releasing hormone induces nuclear factor κB-activation and inhibits apoptosis in ovarian cancer cells. Journal of Clinical Endocrinology and Metabolism 2000 10 3815-3820.
20. Günthert AR, Gründker C, Hollmann K & Emons G. Luteinizing hormone-releasing hormone induces JunD-DNA binding and extends cell cycle in human ovarian cancer cells. Biochemical and Biophysical Research Communications 2002 294 11-15.
21. King JA & Millar RP. Coordinated evolution of GnRHs and their receptors. In GnRH Neurones: Gene to Behavior, pp 51-77. Eds PS Parhar & Y Sakuma. Tokyo: Brain Shuppan Publishers, 1997.
22. Sherwood NM, Lovejoy DA & Coe IR. Origin of mammalian gonadotropin-releasing hormones. Endocrine Reviews 1993 14 241-254.
23. Sealfon SC, Weinstein H & Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocrine Reviews 1997 18 180-205.
24. Gründker C, Günthert AR, Millar RP & Emons G. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. Journal of Clinical Endocrinology and Metabolism 2002 87 1427-1430.
25. Gründker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B & Emons G. The antiproliferative effects of GnRH antagonist Cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I (GnRH-I) receptor. European Journal of Endocrinology 2004 152 141-149.
26. Kurokawa H, Lenferink AE, Simpson JF, Pisacane PI, Sliwkowski MX, Forbes JT & Arteaga CL. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Research 2000 60 5887-5894.
27. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE & Nicholson RI. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003 144 1032-1044.
28. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Baker AJ & Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research 2002 62 5749-5753.
29. Völker P, Gründker C, Schmidt O, Schulz KD & Emons G. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. American Journal of Obstetrics and Gynecology 2002 186 171-179.
30. Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Hölzel F, Schulz KD & Schally AV. High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Research 1993 53 5439-5446.
31. Nicoletti I, Migloriati G, Pagliacci MC, Grignani F & Ricardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. Journal of Immunological Methods 1991 139 271-279.
32. Neill JD, Duck LW, Sellers JC & Musgrove LC. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochemical and Biophysical Research Communications 2001 282 1012-1018.
33. Millar RP, Conklin D, Lofton-Day C, Hutchinson E, Troskie B, Illing N, Sealfon SC & Hapgood J. A novel human GnRH receptor homolog gene: abundant and wide tissue distribution of the antisense transcript. Journal of Endocrinology 1999 162 117-126.
34. Neill JD. GnRH and GnRH receptor genes in the human genome. Endocrinology 2002 143 737-743.
35. Millar RP. GnRH II and type II GnRH receptors. Trends in Endocrinology and Metabolism 2003 14 35-43.
36. Millar R, Lowe S, Conklin D, Pawson A, Maudsley S, Troskie B, Ott T, Millar M, Lincoln G, Sellar R, Faurholm B, Scobie G, Kuestner R, Terasawa E & Katz A. A novel mammalian receptor for the evolutionarily conserved type II GnRH. PNAS 2001 98 9636-9641.
37. Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR & Millar RP. A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology 2003 144 423-436.
38. van Biljon W, Wykes S, Scherer S, Krawetz S & Hapgood J. Type II gonadotropin-releasing hormone transcripts in human sperm. Biology of Reproduction 2002 67 1741-1749.
39. Enomoto M, Endo D, Kawashima S & Park MK. Human type II GnRH receptor mediates effects of GnRH on cell proliferation. Zoological Science 2004 21 763-770.
40. Eicke N, Günthert AR, Viereck V, Siebold D, Béhé M, Becker T, Emons G, & Gründker C. GnRH-II receptor-like antigenicity in human placenta and in cancers of human reproductive organs. European Journal of Endocrinology 2005 (in press).
41. Kim KY, Choi KC, Park SH, Auersperg N & Leung PC. Extracellular signal-regulated protein kinase, but not c-jun N-terminal kinase, is activated by type II gonadotropin-releasing hormone involved in the inhibition of ovarian cancer cell proliferation. Journal of Clinical Endocrinology and Metabolism 2005 90 1670-1677.
42. Kato S, Endoh E, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D & Chambon P. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995 270 1491-1494.
43. Bunone G, Briand PA, Miksicek RJ & Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 1996 15 2174-2183.
44. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L & Horwitz KB. The partial agonist activity of antagonist-occupied steroids receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Molecular Endocrinology 1997 11 693-705.
45. Riese DJ 2nd & Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioassays 1998 20 41-48.
46. Nicholson RI, McClelland RA, Finlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO & Blamey RW. Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. European Journal of Cancer 1993 29 1018-1023.
47. van Agthoven T, van Agthoven TL, Portengen H, Foekens JA & Dorssers LC. Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-71 human breast cancer cells. Cancer Research 1992 52 5082-5088.
48. Gee JM, Harper ME, Hutcheson IR, Madden TA, Barrow D, Knowlden JM, McClelland RA, Jordan N, Wakeling AE & Nicholson RI. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancers in vitro. Endocrinology 2003 144 5105-5117.
49. Jordan JN, Gee JMW, Barrow D, Wakeling AE & Nicholson RI. Increased constitutive activity of PKB/Akt in tamoxifen resistant breast cancer MCF-7 cells. Breast Cancer Research and Treatment 2004 87 167-180.
50. Perez-Tenorio G & Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. British Journal of Cancer 2002 86 540-545.
51. Kraus S, Levy G, Hanoch T, Naor Z & Seger R. Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells: role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways. Cancer Research 2004 64 5736-5744.